Technology
A novel approach to CRISPR
EXCISION
Approach
Dual gRNAs excise large sections of viral DNA, eliminating viral escape and reproduction. The result is curative.
Large Deletion,
No Probability of Escape

DISCOVERY
Platform
Excision's platform enables in silico design of probes to analyze on- and off-target effects and integrates computational methods to design the most effective guide RNAs.
We are transforming drug discovery and target validation from traditional to digital.
THERAPEUTIC
Pipeline
Pre-Clinical In Vitro Studies
Pre-Clinical In Vivo Studies
IND Filing
EBT-101 HIV AAV9 Cas9 dual gRNA Therapeutic
2020
EBT-103 PML/JCV AAV9 Cas9 triplet gRNA T-antigen Therapeutic
Q4 2022
EBT-104 HSV AAV or non-viral Cas9 quad gRNA Therapeutic
Q1 2023
EBT-107 HBV AAV or non-viral CasX dual gRNA Therapeutic
Q2 2023
EBT-201 COVID-19 Treatment & Prevention: CasY, Cas9, Cas13a
In Development